新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 默克 » 默沙东扩大与Akrikhin合作推进产品在俄本土化战略

默沙东扩大与Akrikhin合作推进产品在俄本土化战略

来源:生物谷 2013-08-09 09:49

2013年8月9日讯 /生物谷BIOON/ --美国制药巨头默沙东(Merck & Co)8月8日宣布,已扩大了与俄罗斯本土一流制药公司Akrikhin 的合作,进一步推进默沙东产品制造在俄罗斯本土化战略。

去年,默沙东与Akrikhin在6个关键品牌产品各种剂型和剂量的本土生产达成了协议,涉及心血管疾病、皮肤病、过敏性疾病、麻醉领域。现在,Akrikhin将开始生产默沙东额外5种重要品牌药物,用于俄罗斯当地卫生保健系统。

Akrikhin公司的制造厂将专门用于生产默沙东2型糖尿病药物[捷诺维Januvia(sitagliptin,西他列汀)和Janumet(西他列汀/二甲双胍缓释片)]、支气管哮喘和过敏性鼻炎药物[顺尔宁Singulair(montelukast,孟鲁斯特)]、侵袭性真菌病[Noxafil(泊沙康唑,posaconazole)]、降血脂药[Ezetrol(ezetimibe,依替米贝)],同时也将生产数个产品的不同剂量和不同剂型(片剂和悬浮液)。

近年来,默沙东与其他大多数大型制药公司都积极开拓中国、俄罗斯、印度及巴西等国的新兴市场。

默沙东仍然保留这些产品在俄罗斯本地的推广和销售。(生物谷Bioon.com)

英文原文:Akrikhin expands deal with Merck & Co

Article | 08 August 2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck & Co (NYSE: MRK) within the scope of Merck’s product manufacturing localization strategy in Russia.

Last year, the companies signed an agreement on the production of six key Merck brands in various pharmaceutical forms and dosages at Akrikhin manufacturing site, used for treating cardiovascular, dermatologic and allergenic diseases, as well as for anesthesia applications (The Pharma Letter July 12, 2012). Now, as the second wave of the contract, Akrikhin will start to manufacture five additional Merck brands important for local health care system.

Akrikhin’s manufacturing site will be dedicated to the release of Merck’s drugs for type 2 diabetes mellitus (sitagliptin, Januvia: sitagliptin + metformin, Janumet), bronchial asthma and allergic rhinitis (montelukast, Singulair), invasive mycoses (posaconazole, Noxafil) as well as the hypolipidemic drug (ezetimibe, Ezetrol). Several product dosages and different pharmaceutical forms (tablets and suspension) will be manufactured.

Secondary packaging to being in first-quarter 2014

Secondary packaging for these products will start in first-quarter 2014. The products in tableted form will be further transferred up to the complete manufacturing cycle. Merck still reserves the rights on promotion and sale of the products to be localized.

The decision to expand the partnership is attributed to Merck and Akrikhin aim to provide Russian patients more effectively and timely with products they are demanding. The successive implementation of the first stage of cooperation has confirmed this collaboration to be effective. Thus, Akrikhin has released the first Merck products in its own manufacturing sites ahead of the initially approved schedule for localization project. At present, Akrikhin produces six dosages of Merck medicinal products that are authorized and delivered to the Russian domestic market. The remaining products are at the registration stage. An effective partnership enabled the companies to reach a steady production volume and to make plans to increase it, the Russian drugmaker noted.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库